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ABSTRACT
Introduction: Evidence based treatment for Substance use disorders (SUD) includes psychotherapy
and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin,
may represent potential new treatment options for SUD. This review provides a summary of
(human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor
systems, brain regions and cognitive and emotional processes mediating psilocybin’s effects.
Psilocybin’s chemical structure is similar to that of serotonin. Dysregulations in the serotonin system
are associated with alterations in stress hormones, such as cortisol, and mood disorders. After
psilocybin administration cortisol levels spike and activate the executive control network, with
subsequent increased control over emotional processes, and relief of negative thinking and persis-
tent negative emotions. Preliminary data of ongoing alcohol and smoking addiction studies in
humans shows promising effects of psilocybin administration on substance use. Importantly, psilo-
cybin has a low risk of toxicity and dependence and can be used safely under controlled clinical
conditions.
Areas covered: This paper is a narrative review based on the search terms: psilocybin, substance use
disorder, addiction, depression, serotonin. Literature on potential efficacy and mechanisms of action of
psilocybin in SUD is discussed.
Expert commentary: Recent positive findings with psilocybin need confirmation in well-designed
placebo controlled randomized trials employing a large sample size.
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1. Rational and outline of this review
Substance use disorders (SUDs) are common, but current
pharmacotherapies have only limited success in treating
SUDs. Moreover, medication reducing craving and substance
use is mainly available for alcohol dependence and to a lesser
extent for other substances. Hallucinogens (like lysergic acid
diethylamide [LSD] and psilocybin) may be a group of agents
with potential anti-craving properties and subsequently redu-
cing substance use in SUD patients. For instance, LSD and
psilocybin have previously been shown to effectively alleviate
symptoms of alcohol and nicotine dependence. However, due
to the long plasma half-life (14 h) during which participants
need to be closely supervised, this hallucinogenic drug has a
limited potential in the treatment of SUD. A number of recent
studies have shown therapeutic potential of another halluci-
nogen called psilocybin in the treatment of SUD, which has a
substantially shorter plasma half-life (6 h). In this review, we
provide a summary of (human) studies in which the putative
therapeutic effects of LSD and psilocybin have been tested. In
addition, we shortly discuss the receptor systems, brain
regions, and cognitive and emotional processes that
may mediate psilocybin’s mode of action. Both beneficial
and potentially harmful effects of psilocybin will be discussed.
2. Introduction
For centuries, substance use and SUD have been rather
common. According to the World Health Organization glo-
bal burden of disease study, about 11.8 million people are
suffering from illicit drug dependence worldwide [1]. Several
factors contribute to the risk of developing SUD, including
socioeconomic factors, like lifestyle, life events, adverse life
events (both during childhood and current), drug availabil-
ity or cultural acceptance to use drugs, and psychiatric
disorders such as depression, bipolar disorder, anxiety dis-
orders, and/or schizophrenia [2].
Treatment of SUD often involves both psychological and
pharmacological interventions, such as cognitive beha-
vioral therapy, motivational interviewing, family therapy,
and certain medications. Despite increasing effectiveness
of SUD treatment, still about 50–60% of patients with drug
and alcohol use disorders relapse within 6–12 months after
treatment [3]. New treatments preferably focusing on redu-
cing craving and subsequent substance use are therefore
urgently needed. The hallucinogen psilocybin may provide
a new treatment option for SUD patients, given the bene-
ficial results observed in recent studies (for references, see
below).
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2.1. SUDs
The fifth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5) [4] provides 11 criteria (see Box 1)
for SUD, with a minimum of two required during a 1-year
period in order to meet the criteria for an SUD. SUDs are
defined as chronic disorders of brain reward, motivation,
and memory processes that have gone awry [4]. Activation
of the brain’s reward system may be central to the devel-
opment of SUD. This has been shown by many studies and
has been nicely reviewed by Volkow and Li [5]. Below, we
shortly outline the main mechanisms found to be involved
in SUD.
2.1.1. Monoamines and SUD
The neurobiology of SUD is complex and involves multiple neu-
rotransmitter systems including the dopamine (DA), serotonin [5-
hydroxytryptamine (5-HT)], and corticotropin releasing factor
(CRF) stress systems. All substances of abuse have in common
that they increase DA release in the striatum, and thereby med-
iate reward [5]. The underlying mechanisms are, however,
dependent on the pharmacological profile of the drug. The
psychostimulant cocaine for example inhibits DA, noradrenaline,
and serotonin reuptake transporters (SERTs) and thereby
increases synaptic levels of these monoamines. The ampheta-
mine-type stimulants cause the release of monoamine by rever-
sing monoamine transporter function [5]. Stress system CRF
receptors are found in both the dorsal raphe nucleus (DRN)
and the ventral tegmental area (VTA), brainstem area’s where
serotonergic and dopaminergic cell bodies are located, respec-
tively [5]. This allows a strong interaction between the brain
stress systems and the monoamine neurocircuitries involved in
SUD, including DA and 5-HT. This review only includes a selection
of neuropharmacological findings related to the DA, 5-HT, and
CRF systems, namely those that are targeted by psilocybin. Other
potential neuropharmacological mechanisms of action of psilo-
cybin are beyond the scope of this paper.
2.1.1.1. DA in SUDs. The reward system is at the basis of
normal learning and decision-making through positive reinfor-
cement by DA release [5]. While substances of abuse initially
elicit a massive increase in extracellular DA, long-term excessive
substance use has been proposed to be related with reduced
sensitivity of dopamine D2 receptors, possibly resulting from
downregulation of dopamine D2 receptors [5]. It has been
suggested that this DA hypofunction in the brain triggers a
strong motivation to continue drug use as an attempt to reex-
perience the positive reinforcement as experienced during
initial drug use (positive reinforcement). The DA system also
plays a role in emotional processes. For instance, depression
has been associated with a reward deficit [6]. This overlap in DA
dysfunction may potentially explain the high comorbidity
between SUD and amongst others, depression [7].
2.1.1.2. Serotonin in SUDs. DA release in the reward system
is strongly modulated by 5-HT receptors (specifically 5-HT2A
and 5-HT2C receptors) [8]. Indeed, multiple studies manipulat-
ing central 5-HT levels have reported effects on reward pro-
cessing (for review, see Cools et al. [9]). Additionally, as
reviewed by Muller and Homberg [10], a 5-HT deficit occurring
upon chronic cocaine exposure may be associated with
increased impulsivity, which also feeds addictive behaviors.
Furthermore, it has been demonstrated that stimulation of
serotonergic DRN afferents to the nucleus accumbens
abolishes cocaine reward and diminishes depressive-like beha-
viors in animals [11]. These findings suggest that 5-HT-
mediated changes in emotion can affect addiction-related
disturbances in the reward neurocircuitry.
2.1.2. Neuropeptides and SUDs
Next to the monoamine neurotransmitter systems, neuropep-
tides (like CRF) are also significantly involved in SUD, as
reviewed by Koob [12]. CRF is released from the paraventricu-
lar nucleus (PVN) of the hypothalamus and drives the hypotha-
lamus–pituitary–adrenal axis (HPA-axis). CRF stimulates the
release of adrenocorticotropic hormone (ACTH) in the blood
which in turn stimulates the secretion of cortisol by the adre-
nal cortex. The HPA-axis contains a negative feedback
mechanism, which allows cortisol – through binding at gluco-
corticoid receptors in the hippocampus and prefrontal cortex
– to reduce CRF release by the PVN, and subsequently to
reduce adrenal secretion of cortisol.
The HPA-axis plays an important role in substance use. Animal
studies have demonstrated that removal of the adrenal axis
hinders the acquisition of drug self-administration, suggesting
that cortisol (corticosterone in animals) is needed for the initial
behavioral response to drugs. It has been thought that cortisol/
corticosterone signals arousal and also exerts rewarding effects
involved in the initial acquisition of drug use behavior [13].
The HPA-axis has also been shown to be relevant in the
maintenance phase of drug self-administration in animals,
through changes in higher order emotional regions like amyg-
dala, where CRF is abundantly expressed [14]. It has been
demonstrated that repeated activation of the dopaminergic
VTA (by substance use) and stimulation of DA receptors in the
amygdala activate the CRF system in the amygdala [15].
Box 1. The DMS-5 includes 11 criteria for the assessment of substance
use disorders (SUD). A minimum of two criteria is required to meet the
criteria of SUD. The total number of criteria someone meets determines
the severity of the SUD. Two or three symptoms indicate a mild SUD,
four or five symptoms indicate a moderate SUD, and six or more
symptoms indicate a severe SUD.
1. Taking the substance in larger amounts or for longer than meant to
2. Wanting to cut down or stop using the substance but not
managing to do so
3. Spending a lot of time getting, using, or recovering from use of the
substance
4. Cravings and urges to use the substance
5. Not managing to do what you should at work, home, or school,
because of substance use
6. Continuing to use, even when it causes problems in relationships
7. Giving up important social, occupational, or recreational activities
because of substance use
8. Using substances again and again, even when it puts you in danger
9. Continuing to use, even when you know you have a physical or
psychological problem that could have been caused or made worse
by the substance
10. Needing more of the substance to get the effect you want (tolerance)
11. Development of withdrawal symptoms, which can be relieved by
taking more of the substance
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Furthermore, there are tight interactions between the 5-HT
and CRF systems at various levels. For instance, it has been
reported that a cluster of serotonergic neurons in the DRN
expresses CRF and that these neurons project to CRFergic
neurons in the central nucleus of the amygdala [16].
Furthermore, rats lacking SERT display high basal corticoster-
one levels in blood plasma [17] as well as reduced cocaine-
induced 5-HT release [18], and increased compulsive cocaine
self-administration [19,20] compared to wild-type animals. It
has been suggested that the CRF system in the amygdala is
implicated in compulsive substance use during later stages of
SUD, when a negative emotional state is the motivational
factor to continue drug use [12] (negative reinforcement).
2.2. Psilocybin
In the 1950s, a group of drugs was discovered that had the
potential to alter consciousness. These new mind altering
drugs were called hallucinogens. The most extensively studied
hallucinogen is LSD. Several studies suggested an anti-SUD
potential, by showing improvements in self-acceptance and
interpersonal relationships, and reductions in craving and
alcohol use in the treatment of alcohol dependence [21,22].
However, the lack of randomized, double-blind, placebo-con-
trolled designs hamper researchers to draw firm conclusions
concerning LSD’s efficacy in alcohol dependence [23,24].
Moreover, several studies did not find evidence for the efficacy
of LSD in the treatment of alcohol dependence [25–27]. As a
result of its recreational popularity during the 1960s, its abuse
potential LSD was banned in 1967, greatly reducing scientific
research in this field. Recently, another hallucinogen, psilocy-
bin, has gained popularity in neuropsychological research.
Psilocybin, a hallucinogenic substance in psilocybin-containing
mushrooms, has been shown to increase trait openness [28],
cognitive and behavioral flexibility [29], and ratings of positive
attitude, mood, social effects, and behavior at the 2-month
and 14-month follow-up [30]. One double-blind study even
reported persistent positive changes in attitude and behavior
after a single dose of psilocybin for up to 25 years [31].
Psilocybin has also been shown to decrease depressive symp-
toms in terminally ill cancer patients [32]. These findings sug-
gest that psilocybin might be a valuable compound for the
treatment of psychiatric conditions.
Similar promising findings have been observed in addic-
tion research (see Table 1), where participants typically
receive 0.3–0.4 mg/kg of psilocybin in two to three sessions.
A recent pilot study in alcohol-dependent patients on the
efficacy of psilocybin in alcohol dependence showed a
significant reduction in both percentage of drinking days
and heavy drinking days, with large effect sizes [33].
Furthermore, a recent study investigating psilocybin in
tobacco dependence demonstrated that 80% of the partici-
pants had quit smoking after a 6-month follow-up, thereby
substantially exceeding success rates for other behavioral
and/or pharmacological therapies [34]. In the latter study,
participants were also asked why they thought psilocybin
helped in quitting smoking. The most common reasons
were ‘changing orientation toward the future, so that long-
term benefits outweighed immediate desires (73%); strength-
ening participants’ beliefs in their ability to quit (73%); and
changing life priorities/values, such that smoking was no
longer more important than quitting (68%)’.
It is important to note that both studies on the effect of
psilocybin in SUD patients did not assess the effect of psilo-
cybin on relapse rates after a period of abstinence. This is a
lack of knowledge in the current literature that future studies
should address. However, several additional studies do pro-
vide some supportive evidence for the therapeutic potential of
psilocybin for SUD treatment and relapse prevention [35,36].
In a study by Hendricks et al. [36], it was found that hallucino-
gen use predicted reduced recidivism among substance-
involved offenders and it was suggested that hallucinogens
may promote alcohol and other drug abstinence and prosocial
behavior. In order to examine the mechanistic contributions of
hallucinogens, Burdick and Adinoff [35] have proposed an
experimental design for a clinical trial to evaluate the efficacy
of psilocybin in addiction treatment.
As outlined above, an elaborate (mechanistic) theory
explaining the potential mechanism of psilocybin’s effi-
cacy, as a treatment for SUD, is currently lacking. This
review aims to discuss scientific evidence for the potential
therapeutic effects of psilocybin for SUD. Current findings
suggest that psilocybin may support drug-dependent indi-
viduals in overcoming their SUD [37]. Potential mechan-
isms are discussed.
2.2.1. History of psilocybin-containing mushroom use
Psilocybin is the main psychedelic ingredient of mushrooms of
the genus Psilocybe [38] that has been used both in the lay
scene, as in various studies for the treatment of anxiety and
obsessive compulsive disorder [32,39]. Ritual use of psilocybin-
containing mushrooms across the globe dates back millennia
and is still regionally practiced today. Robert G. Watson first
introduced these mushrooms to the Western society in 1957.
Shortly after being introduced to the general public, it was
scheduled as a class I drug in 1970 and human experiments
steadily terminated. However, given its limited side effects (see
Table 1. Evidence table summarizing the results of human studies on the use of psilocybin for treating substance use disorders. Participants in both studies received
similar doses of psilocybin, however, at different timepoints after the start of PST.
Author Type of SUD Sample size Follow-up period Results Administration procedure
(Bogenschutz
et al. [33])
Alcohol
dependence
n = 10 Weeks 4, 8, 12,
24, and 36
Significant reduction in
percentage drinking days
and heavy drinking days
Session 1: 4 weeks after PST 0.3 mg/kg
Session 2: 8 weeks after PST 0.4 mg/kg
(Johnson
et al. [34])
Tobacco
dependence
n = 15 Weeks 2–15,
6-month follow-up
80% abstinence at
6-month follow-up
Session 1: 5 weeks after PST 0.29 mg/kg
Session 2: 7 weeks after PST 0.43 mg/kg
Session 3: 13 weeks after PST 0.43 mg/kg
PST: Psychosocial treatments; SUD: substance use disorders.
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below) and pharmacological properties, human experimental
research on the neuropsychological effects of psilocybin has
revived since the late 1990s (for review [40,41]).
2.2.2. Metabolism and minimal toxicity of psilocybin
The prodrug psilocybin is rapidly dephosphorylated by alkaline
phosphatase [42] in the intestinal mucosa to psilocin. The
dephosphorylation of psilocybin is not essential for the psycho-
tropic action but does increase its potency by a factor 1.4 [42].
After absorption, psilocybin is distributed in all tissues, includ-
ing the brain, where it exerts its psychedelic properties. It is
then glucuronidated by endoplasmic enzymes and subse-
quently excreted from the body by the kidneys (65%), liver,
and intestine (15–20%) [43]. Although some authorities warn
about the dangers of using psilocybin-containing mushrooms,
multiple studies and clinical trials revealed a low toxicity of
psilocybin [44,45]. For example, studies in rats and pigs showed
no evidence of toxicity for heart and intestine cells [46], nor for
the brain [47]. We encountered two reported fatalities of psilo-
cybin use. In one case, a person died after ingestion of an
extremely high dose of Psilocybe semilanceata, resulting psilo-
cybin plasma levels of 4 µg/mL [48]. In another case, a heart
transplant recipient appeared to have plasma psilocin levels of
30 µg/mL [49]. Despite the mild physiological effects, including
hypertension and tachycardia, it cannot be excluded that extre-
mely high doses of psilocybin cause LSD-overdose-like effects
such as hyperthermia, respiratory failure, or even coma [50]. It is
however unclear at what plasma levels, such effects occur.
2.2.3. 5-HT neuropharmacology of psilocybin
The structural formula of psilocybin is very similar to 5-HT
(Figure 1). Therefore, it is not surprising that psilocybin binds
with high affinity to 5-HT receptors. The neurophysiological
action of psilocybin has been found to be dependent on 5-HT
receptor distribution in different cell types. This can conse-
quently lead to increased or decreased neuronal activity
depending on the specific brain area [51].
Psilocybin binds to multiple 5-HT receptors, but it has the
highest affinity for 5-HT2A (Ki = 6 nM) and to a lesser extent at
5-HT1A receptors (Ki = 190 nM) [53]. A study by Vollenweider
et al. [54] reported that pretreatment with ketanserin, a selec-
tive 5-HT2A receptor antagonist, dose dependently blocked
the psychological effects of psilocybin. Similarly, risperidone,
a 5-HT2A/D2 receptor antagonist, completely blocked the psy-
chotropic effects of psilocybin [54]. Animal studies in rats
showed that various 5-HT2 antagonists block the stimulant
effects of LSD [55]. Fiorella et al. [55] also found a correlation
between 5-HT2A antagonist binding affinity and the degree of
stimulant effect of the hallucinogen. Another study reported
similar findings regarding the behavioral effects of hallucino-
gens; a near perfect correlation was found between the beha-
vioral potency of hallucinogens and its affinity to the 5-HT2A
receptor [56].
Whereas the 5-HT2A receptor plays a key role in the char-
acteristic effects of many hallucinogens, it has been suggested
that in animals, the nonselective interaction of hallucinogens
with other 5-HT receptors contributes to behavioral effects
such as lateral head weaving, hind limb abduction, backward
locomotion, and lower lip retraction (for review, see
Halberstadt and Geyer [57]). A study by Strassman [58] sug-
gested that 5-HT1A receptor agonism may act to buffer 5-HT2A-
mediated psychedelic effects.
2.2.4. Neuroanatomical localization of 5-HT receptors
The neuroanatomical distribution of 5-HT receptors explains
the behavioral effect of psilocybin. Several studies show high
5-HT2A receptor densities in cerebral cortical areas including the
frontal, parietal, temporal, and occipital lobe, which are largely
involved in memory, attention, perceptual awareness, thought,
language, and consciousness as well as cognitive control [59].
Key behavioral components of 5-HT function in cognitive con-
trol include being able (1) to hold information in mind including
complicated representational structures, to mentally manipu-
late that information, and to act on the basis of it, (2) to act on
the basis of choice rather than impulse, exerting self-control by
resisting inappropriate behaviors, and (3) to quickly and flexibly
adapt behavior in response to changing environments [60].
The amygdala, a brain area that functions as a sensory inter-
face during emotional learning, also shows high expression of
5-HT2 receptors. Specifically, the 5-HT2A receptor is expressed
on both pyramidal (i.e. excitatory) and non-pyramidal neurons
in the amygdala [61] and plays a critical role in the formation of
emotional memories [62]. The amygdala, together with the
ventral striatum, is believed to play an important role in asso-
ciative processes in SUD through interactions between primary
reinforcement, psychomotor activation, Pavlovian condition-
ing, and cue-induced drug seeking behavior [63].
The 5-HT2A receptors are also expressed in the PVN and
implicated in the regulation of the HPA-axis and anxiogenic
responses [64]. Chronic stress desensitizes these receptors
[65], whereas withdrawal from drug self-administration has
been associated with 5-HT2A receptor supersensitivity in the
Figure 1. Chemical structures of psilocybin, psilocin, and its endogenous analogue serotonin. Edited from Stebelska [52].
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PVN [66]. 5-HT2A receptors may thus strongly influence the
emotional state of an individual and involve emotional distur-
bances observed in SUD.
Finally, 5-HT1A receptors are largely found in the hippocam-
pus, septum, neocortex, raphe nucleus, and amygdaloidal
nuclei [67], which are involved in mediating cognitive and
emotional processes, respectively. High densities of 5-HT1A
binding have also been found in the limbic systems of several
mammalian species including humans. As a result, also 5-HT1A
receptors are involved in mediating the emotional state of
individuals and patients with SUD.
2.3. Putative modes of action of psilocybin in SUD
The predominant action of psilocybin on central 5-HT2A and 5-
HT1A receptors suggests that emotional and cognitive pro-
cesses regulated by brain regions containing high levels of
these serotonergic receptors may play an import role in the
mode of action of the drug. Indeed, several authors suggest a
dual process model for SUDs, where an unbalance in cognitive
control functions and emotional processes contributes to the
development and persistence of SUDs. This model aligns well
with the National Institute of Mental Health (NIMH) roadmap
for bridging the gap between neurobiological insights in the
mechanisms and the clinical classification of mental disorders,
using Research Domain Criteria (RDoC; see also Insel, Thomas
R.; Lieberman, Jeffrey A. (13 May 2013). ‘DSM-5 and RDoC:
Shared Interests’ (Press release). NIMH). Below, we will elabo-
rate on how psilocybin may exert its anti-addictive properties,
within this conceptual framework of SUDs. We especially
emphasize on psilocybin’s potential effects on negative emo-
tional states and stress (RDoC domain: negative valence sys-
tems), and cognitive inflexibility and compulsivity (RDoC
domain: cognitive systems), and two key features displayed
in patients with SUD.
2.3.1. Psilocybin: effects on negative emotional states and
stress
Substance dependence is strongly associated with negative
affect and stress, as also observed in major depressive disorder
(MDD) [7]. Similar to MDD, it has been shown that individuals
suffering from SUD suffer from persistent dysregulations in
their emotional (amygdala-mediated) and stress (HPA-axis-
mediated) systems [68]. As outlined above, the amygdala,
which is strongly innervated by serotonergic neurons [69], is
known to be involved in the processing of emotions and
related memories. The 5-HT1A and the 5-HT2A receptors play
a central role in these processes [70,71]. Increased prefrontal
cortex 5-HT2A and decreased hippocampal 5-HT1A receptor
expression and/or binding have been shown to contribute to
the pathophysiology of negative affect, depression, and sui-
cide [72,73]. This has led several researchers to propose that
postsynaptic 5-HT1A and 5-HT2A receptors exert opposing
effects in the regulation of mood [74]. A disturbed balance
between these receptors has been thought to contribute to
depression [75] but may also be relevant for SUD. Since restor-
ing this balance is thought to be necessary for antidepressant
action [41], this may also be true for the treatment of SUD.
A recently published fMRI study found decreased amygdala
reactivity during acute psilocybin treatment which was asso-
ciated with an increase in positive mood in healthy volunteers
[76]. Similarly, a study on the physiological and psychological
effects of low-dose psilocybin administration in terminal can-
cer patients showed a sustained reduction in trait anxiety that
reached significance at the 1- and 3-month points after treat-
ment [32]. These phenomena may also be relevant for the
normalization of amygdala hyperactivity in SUD associated
with cue-induced drug craving and anxiety [77]. Although
SUD and cancer are two entirely different diseases, psilocybin
may thus exert long-term anxiolytic effects in humans, includ-
ing SUD patients.
Chronic stressful circumstances are represented by a dys-
regulation and increase in basal cortisol levels. A study by
Ouellet-Morin et al. [78] showed that maltreated/bullied
children had significantly lower cortisol responses to a stres-
sor compared to children who were not bullied or maltreated.
Furthermore, among maltreated/bullied children, lower corti-
sol responses were, in turn, associated with more behavioral
and social problems [78]. Early life adversity and aberrant
function of the HPA-axis have also been associated with
MDD [79] and SUD [80], although the precise mechanisms
are not fully clear yet. 5-HT receptor activation in the hypotha-
lamus has been suggested to induce CRF secretion and con-
comitant HPA-axis activation. For example, the 5-HT2A
receptor agonist DOB ((+-1-(2,5-dimethoxy-4-bromophenyl)-
2-aminopropane) was able to activate the HPA-axis and dose
dependently increase plasma ACTH and cortisol [81]. Multiple
studies showed that psilocybin could also temporarily
increase cortisol, ACTH, prolactin, and thyrotropin levels with-
out a stress test, which returned to normal after 5 h [82].
Although an increase in cortisol levels seems contradictory
to achieving stress reduction, studies by Lupien et al. [83]
showed cortisol is necessary for learning and memory in
humans. A psilocybin-induced cortisol spike may activate
large-scale brain networks, which are clusters of intercon-
nected brain regions mediating a well-defined cognitive func-
tion. Networks playing a key role in SUD [84] involve the
default mode network (DMN, including the medial prefrontal
cortex, posterior cingulate cortex, precuneus, hippocampus,
and inferior parietal cortex), the executive control network
(ECN, including the dorsolateral prefrontal cortex, frontal eye
fields, and dorsal posterior parietal cortex), [85] and the sal-
ience network (SN, including the amygdale, insula, anterior
cingulate cortex, and ventral striatum) [86]. This triple network
model proposed by Menon [86] and involving the SN, DMN,
and ECN was adapted by Sutherland et al. [87] who suggested
that the SN is important for dynamic switching between the
DMN and ECN. When there is a cortisol spike, the SN is
immediately activated, in order to steer attention toward the
stressor. A study published recently by Kraehenmann et al.
[88] found that psilocybin reduced stressor-induced modula-
tion of amygdala connectivity (part of the SN) which may
explain the potential of psilocybin to shift emotional biases
away from negative during emotional processing [89]. This
may also affect the reallocation of the available attentive
resources to other networks, like the DMN and ECN. Data
suggest that the DMN is activated within 100 min after
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psilocybin administration [82]. Activation of the DMN leads to
an introversive phase (directing thoughts and feelings toward
oneself). During this period, the initial stress and subsequent
withdrawal induced anxiety-related and depression-like symp-
toms may be emotionally processed. Finally, the ECN is acti-
vated, which occurs 60–90 min after onset of a stressor. The
ECN allows one to orient to external tasks and improve
focused attention and working memory [90].
2.3.2. Role of 5-HT2A and 5-HT1A in cognitive inflexibility
and compulsivity
Cognitive flexibility enables an individual to switch behavior in
response to environmental changes. Such a disengagement
from ongoing behavior requires multiple cognitive compo-
nents of decision-making. It is clear that the ability to change
a certain behavior is imperative in order to resolve SUD.
Multiple studies found that both psilocybin and LSD enhanced
reversal learning in both rats and primates [91,92]. Of interest,
behavioral inflexibility is strongly modulated by 5-HT2A recep-
tors. It has been demonstrated that 5-HT2A receptor antagon-
ism impairs behavioral flexibility by increasing perseveration
[93], suggesting that 5-HT2A agonism has a beneficial effect on
behavioral flexibility. Indeed, 5-HT2A receptors in the orbito-
frontal cortex facilitate reversal learning [94]. The 5-HT1A
receptor is also implicated in behavioral flexibility but may
be limited to restore flexibility when impaired in disease mod-
els [95]. Behavioral flexibility is furthermore dependent on the
prefrontal cortex, insula, basal ganglia, anterior cortex [96],
and posterior parietal cortex [97]. Since these brain regions
are components of the SN and ECN, respectively, it is possible
that psilocybin increases behavioral flexibility by reducing SN
and increasing ECN activity (see Section 2.3.1).
2.3.3. Side-effects and addictive properties of psilocybin
The side effects of using psilocybin mainly depend on personal
expectations and the environmental setting in which a subject
uses it [98]. A pooled analysis study investigating the effects of
different predictor variables on the acute response to psilocybin in
healthy volunteers found that being in an emotionally excitable
and active state immediately before drug intake, and having
experienced few psychological problems in the weeks before
were most strongly associated with pleasant and mystical-type
experiences [99]. Altered perceptions, including hallucinations,
and intensified emotions can result in dangerous behavior during
nonmedical administration [47]. Such complications can usually
be prevented by the following rules: proper education before
administration, administration in a calm and safe environment,
and guidance of an experienced user during the experience [47].
It has been shown that the use of hallucinogenic substances
may accentuate or trigger psychotic symptoms or evoke non-
specific psychotic episodes in patients suffering from depression,
schizophrenia, or psychosis [100]. However, it is not likely that
hallucinogenic substances cause psychiatric conditions in non-
predisposed individuals. The prevalence of prolonged psychiatric
symptoms after use of LSD has been investigated in healthy
subjects and psychiatric patients. It was estimated that 0.08–
0.09% of the healthy volunteers and 0.18% of psychiatric patients
experienced prolonged psychiatric symptoms as a consequence
of LSD use [100]. Prolonged psychosis in healthy subjects after a
single dose of psilocybin is extremely rare and in most cases
associated with a psychotic predisposition [47]. A thorough
medical and psychiatric screening and strong interpersonal sup-
port from session monitors before, during, and following ses-
sions are key factors in minimizing long-lasting adverse
psychological effects of psilocybin administration.
The risk of substance dependence or addiction to psilocybin
appears to be very low [101]. Users of psilocybin quickly build
up a tolerance to the reinforcing effects of the substance.
However, in humans, psilocybin was reported not to cause
craving or withdrawal [47]. In a recent animal study on self-
administration in monkeys, three out of four animals showed
very low self-administration rates above placebo [102]. For
these animals, psilocybin initially had a reinforcing effect.
Animals were unable to maintain self-administration behavior.
These observations may be explained by the fact that psilocy-
bin does not directly affect the mesolimbic dopaminergic path-
way and thus does not activate the above a brain-reward
system directly.
3. Summary and conclusion
Taken together, we propose here that psilocybin may have
therapeutic effects in the treatment of SUD. With the reported
limited amount of side effects, and potential beneficial effects
of psilocybin in SUD, we strongly believe that there are valid
reasons to further investigate the therapeutic efficacy and
safety of psilocybin as a potential SUD treatment. We specifi-
cally hypothesize two mechanisms of action of psilocybin that
might mediate its anti-addictive properties. On the one hand,
psilocybin may exert its anti-addictive properties by beneficial
effects on negative emotional states and stress. On the other
hand, psilocybin may improve cognitive inflexibility and com-
pulsivity. These effects may be mediated through binding of
psilocybin to central 5-HT2A and 5-HT1A receptors.
Given that psilocybin affects 5-HT2A receptor-mediated sig-
naling implicated in emotional processes, the neuroendocrine
system, and behavioral flexibility, we hypothesize that psilocybin
overall may improve cognitive functioning and alleviate anxiety-
related and depression-like symptoms associated with SUD.
Research on the efficacy of psilocybin on SUD is still limited to
a handful of published studies to date. As a result, many impor-
tant questions related to the use of psilocybin as a complement
to current treatment of SUD, and its workingmechanisms remain
unanswered. For instance, it is unknown if and how psilocybin
interacts with existing behavioral and pharmacological treat-
ments for SUD. Qualitative analysis of experiences of people
that used psilocybin may also shed some light on the individual
processes in overcoming their SUD. Clearly, before psilocybin can
be implemented as a treatment option for SUD, more extensive
research is needed to address these and other issues. We have
outlined further outstanding issues in our expert opinion.
4. Expert commentary
Most research on psychedelics was performed in the 1950–
1970s, but these substances became illegal because of their
hallucinogenic effects. Many studies tested the potential
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of the mind-altering effects of psychedelics for treating psy-
chiatric disorders, including SUD. Several studies have
reported significant reductions in substance use and craving
in SUD patients, after administration of psychedelics, including
psilocybin. However, many of these studies lacked a double-
blind controlled design, which limits the level of evidence.
Furthermore, several studies did not confirm efficacy of psy-
chedelics in SUD. Nonetheless, given the recently published
positive findings and neuropharmacological properties of psi-
locybin outlined above, we believe that psilocybin holds
potential for the treatment of SUD.
Recently, several studies reported positive results of psilocy-
bin in amongst others alcohol and nicotine dependence.
Considering the previous conflicting results on the efficacy of
psychedelics in SUD, these recent positive findings with psilocy-
bin need confirmation in well-designed placebo-controlled ran-
domized trials employing a large sample size. It is also important
to determine whether the efficacy of psilocybin is dependent on
the type of SUD. It is conceivable that psilocybin, acting through
5-HT receptors, differentially influences psychostimulant (5-HT-
dependent) and opiate (5-HT-independent) SUD. It also remains
to be clarified whether and how 5-HT2A receptors modulate SN,
DMN, and ECN activity in SUD, and whether genetic variation
within the 5-HT2A and 5-HT1A receptors causes individual differ-
ences in responsivity to psilocybin. Also, preexisting trait char-
acteristics, including anxiety and personality, may be of
influence on the efficacy of psilocybin, as these traits may be
shaped by neural network patterns that are targeted by psilo-
cybin. Furthermore, it is not clear yet whether gender plays a
role in the efficacy of psilocybin for SUD. Gonadal hormones
interact with cortisol and thereby may influence the psilocybin-
induced cortisol spike and the subsequent cascade of neural
network activation patterns. Along the same line, it remains to
be determined whether changes in HPA-axis function in differ-
ent types of SUD patients influence the efficacy of psilocybin.
Studies are required to unravel the anti-addictive potential of
psilocybin. In animal studies, this can be addressed by studying
whether psilocybin reduces the self-administration of sub-
stances of abuse and specifically the drug-, cue-, and stress-
induced reinstatement of drug-seeking behavior. A controversial
question is whether psilocybin use may have preventive effects
for the development of SUDs, for example when used by ado-
lescents and young adults. Animal studies are well suitable to
explore preventive efficacy of psilocybin for SUDs and investi-
gate toxicity for the developing brain in adolescents and young
adults. In humans, the efficacy of psilocybin to reduce relapse
during 6–12 month longer follow-up measures need to be
assessed. Ultimately, such studies and research into the working
mechanisms of psilocybin may identify new treatment targets
for the discovery of new medications.
5. Five-year view
We expect that the field of psychedelic research will signifi-
cantly increase over the coming years. The recreational use of
psychedelics in America has remained popular among
younger adults since the 1960s with prevalence rates as high
as 20%. This shows that the subject of psychedelics is still very
alive in the Western society. What is more, last year marijuana
has been legalized in several US states. Hence, there is a shift
in how society perceives these mind-altering substances. It is
possible that psychedelic drugs are being used as a form of
self-medication by some individuals. It is interesting for future
research to study what kind of psycho-behavioral background
regular users have and why and with whom they use it. This
may shed more light on the motivation and perhaps some
psycho-emotional modes of action of psilocybin.
Key issues
● Psilocybin is a hallucinogen with low risk of toxicity and
dependence
● Psilocybin’s chemical structure is similar to that of serotonin
● Psilocybin acts predominantly through the 5-HT2A recep-
tor, and to a lesser extend through the 5-HT1A receptor
● Psilocybin potentially exerts effects on the negative valence
system and on cognitive systems
The serotonergic action of psilocybin may contribute to the
reduction in addictive behaviors by enhancing cognitive con-
trol and increasing control over emotions.
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